Gennova Biopharmaceuticals Ltd has unveiled HAMSYL Junior, marking the debut of India’s first pediatric cancer care drug with a pack size of pegaspargase.

Specifically designed for children suffering from Acute Lymphoblastic Leukaemia (ALL), a rare blood cancer, the drug is now available in a 1,500 IU pack.

This launch follows Gennova’s earlier introduction of HAMSYL in 2014, which played a pivotal role in improving accessibility to ALL treatment by providing an affordable alternative in a 3750 IU pack.

The company's commitment to enhancing ALL management led to HAMSYL being recognized as a first-line therapy in 2019, demonstrating its efficacy and safety.

Dr. Sanjay Singh, CEO of Gennova Biopharma Limited, highlighted the significance of HAMSYL Junior's introduction in advancing pediatric oncology care.

The launch aims to address cost barriers and align with global standards, reinforcing Gennova's commitment to improving cancer treatment accessibility for children in India.